Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:BEAM NASDAQ:CDTX NASDAQ:NBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$38.42+1.5%$38.54$26.20▼$63.50$1.77B1.42720,372 shs682,484 shsBEAMBeam Therapeutics$19.94-4.5%$18.84$13.52▼$35.25$2.02B2.142.15 million shs4.79 million shsCDTXCidara Therapeutics$62.15-1.6%$59.71$10.14▼$69.36$1.58B1.29379,426 shs542,424 shsNBTXNanobiotix$8.71+0.1%$6.97$2.76▼$10.59$417.56M0.4711,792 shs12,285 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+4.12%+7.01%-5.63%-19.85%BEAMBeam Therapeutics0.00%+27.63%+18.50%+14.91%-10.42%CDTXCidara Therapeutics0.00%-3.40%+1.89%+148.90%+452.19%NBTXNanobiotix0.00%-4.42%+15.79%+82.39%+61.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$38.42+1.5%$38.54$26.20▼$63.50$1.77B1.42720,372 shs682,484 shsBEAMBeam Therapeutics$19.94-4.5%$18.84$13.52▼$35.25$2.02B2.142.15 million shs4.79 million shsCDTXCidara Therapeutics$62.15-1.6%$59.71$10.14▼$69.36$1.58B1.29379,426 shs542,424 shsNBTXNanobiotix$8.71+0.1%$6.97$2.76▼$10.59$417.56M0.4711,792 shs12,285 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+4.12%+7.01%-5.63%-19.85%BEAMBeam Therapeutics0.00%+27.63%+18.50%+14.91%-10.42%CDTXCidara Therapeutics0.00%-3.40%+1.89%+148.90%+452.19%NBTXNanobiotix0.00%-4.42%+15.79%+82.39%+61.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.88Moderate Buy$97.29154.00% UpsideBEAMBeam Therapeutics 3.07Buy$48.45143.00% UpsideCDTXCidara Therapeutics 3.11Buy$64.141.84% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00-7.73% DownsideCurrent Analyst Ratings BreakdownLatest NBTX, APGE, CDTX, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/28/2025APGEApogee TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $87.008/14/2025APGEApogee TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$90.008/8/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$59.00 ➝ $66.008/8/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$53.00 ➝ $74.008/8/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$54.00 ➝ $74.008/6/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$25.00 ➝ $21.007/21/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/9/2025CDTXCidara TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$69.00(Data available from 9/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ABEAMBeam Therapeutics$63.52M31.76N/AN/A$8.86 per share2.25CDTXCidara Therapeutics$1.27M1,257.72N/AN/A$14.92 per share4.22NBTXNanobiotix$39.18M10.61N/AN/A($1.51) per share-5.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)CDTXCidara Therapeutics-$169.83M-$11.13N/AN/AN/AN/A-50.81%-42.46%11/6/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)Latest NBTX, APGE, CDTX, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025APGEApogee Therapeutics-$1.03-$1.13-$0.10-$1.13N/AN/A8/7/2025Q2 2025CDTXCidara Therapeutics-$1.87-$1.65+$0.22-$1.65N/AN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3616.36BEAMBeam TherapeuticsN/A6.756.75CDTXCidara TherapeuticsN/A16.4516.45NBTXNanobiotixN/A1.041.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%BEAMBeam Therapeutics99.68%CDTXCidara Therapeutics35.82%NBTXNanobiotix38.81%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%BEAMBeam Therapeutics3.50%CDTXCidara Therapeutics7.64%NBTXNanobiotix3.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.11 million26.39 millionOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableCDTXCidara Therapeutics9025.36 million23.42 millionNo DataNBTXNanobiotix10047.94 million46.29 millionNot OptionableNBTX, APGE, CDTX, and BEAM HeadlinesRecent News About These CompaniesNanobiotix to Present at H.C. Wainwright Investment ConferenceSeptember 5 at 5:56 AM | theglobeandmail.comNanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Stock Price Down 5.2% - Here's WhyAugust 23, 2025 | marketbeat.comShort Interest in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) Increases By 209.8%August 18, 2025 | marketbeat.comGuggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX)July 25, 2025 | theglobeandmail.comNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) - MorningstarJuly 8, 2025 | morningstar.comMNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)July 7, 2025 | globenewswire.comNANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ConferenceMay 28, 2025 | globenewswire.comNanobiotix Provides First Quarter 2025 Operational and Financial UpdateMay 21, 2025 | globenewswire.comNanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 12, 2025 | globenewswire.comNanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further EvaluationMay 5, 2025 | finanznachrichten.deNanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic CancerMay 5, 2025 | globenewswire.comNanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference CallApril 30, 2025 | globenewswire.comNanobiotix price target lowered to $8 from $12 at GuggenheimApril 5, 2025 | markets.businessinsider.comNanobiotix (NBTX) Gets a Hold from UBSApril 5, 2025 | markets.businessinsider.comNanobiotix S.A. (NBTX) Q4 2024 Earnings Call TranscriptApril 3, 2025 | seekingalpha.comNANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial ResultsApril 2, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)April 2, 2025 | theglobeandmail.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025March 31, 2025 | globenewswire.comNanobiotix reports promising NSCLC treatment study resultsMarch 29, 2025 | investing.comNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCMarch 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBTX, APGE, CDTX, and BEAM Company DescriptionsApogee Therapeutics NASDAQ:APGE$38.42 +0.55 (+1.45%) As of 04:00 PM EasternApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Beam Therapeutics NASDAQ:BEAM$19.94 -0.94 (-4.50%) Closing price 04:00 PM EasternExtended Trading$20.20 +0.26 (+1.30%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Cidara Therapeutics NASDAQ:CDTX$62.15 -1.02 (-1.61%) Closing price 04:00 PM EasternExtended Trading$62.06 -0.09 (-0.14%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Nanobiotix NASDAQ:NBTX$8.72 +0.02 (+0.29%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Eyes on the Sky: AST SpaceMobile Prepares for Commercial Launch Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
